Pharma's $50B Problem Has a New Cure: Patient-Powered Data

NEW YORK, NY – June 02, 2026 – In the high-stakes world of pharmaceutical research, data is the most valuable currency. Yet, for decades, the industry has relied on a system that is fundamentally broken, costing an estimated $50 billion annually in inefficiencies. Today, New York-based Novellia announced an $18 million Series A funding round to scale a solution that doesn't just patch the system, but rebuilds it from the ground up. Led by Spark Capital, the investment brings Novellia's total funding to $28 million and will fuel the expansion of its platform, which is built on a radical premise: the most accurate and complete health data comes directly from the patient.

Coinciding with the funding is the launch of its patient-facing mobile app, a move that signals a deeper commitment to its core strategy. While most real-world data (RWD) companies act as brokers, stitching together fragmented datasets from insurance claims and hospital records, Novellia is creating an entirely new value chain. It provides patients with a free tool to unify their own health histories and then gives them the choice to contribute that de-identified data to science. This patient-centric model isn't just an ethical high road; it's a strategic gambit to deliver a data product so comprehensive and clean that it fundamentally changes how new medicines are developed.

The Broken Value Chain of Health Data

To understand the significance of Novellia's approach, one must first appreciate the scale of the problem it aims to solve. Researchers have long depended on RWD to see how treatments perform in the messy reality outside pristine clinical trials. But the data they receive is often incomplete, latent, and devoid of crucial context. The current ecosystem is dominated by third-party aggregators navigating a labyrinth of disparate electronic health record (EHR) systems, billing codes, and pharmacy scripts. The result is a patchwork quilt of information that often fails to capture the full patient journey.

"Behind every patient is a fragmented, incomplete record of their life," said Shashi Shankar, Co-Founder and CEO of Novellia, in a statement. Shankar's motivation is deeply personal, rooted in his experience with his grandfather's cancer journey and his professional frustration within the pharma industry. "We were developing therapies without ever seeing the full picture. The system failed patients and researchers at the same time." This failure isn't just a logistical headache; it's a massive financial drain and a significant barrier to innovation. The $50 billion figure cited by the company represents the cost of acquiring and cleaning this imperfect data, a sum that yields surprisingly low-fidelity results.

This fragmented reality places an immense administrative burden on the sickest patients, who spend countless hours chasing down records and repeating their complex histories to each new specialist. Novellia's platform is designed to eliminate this friction, creating a win-win scenario where patients gain an invaluable personal tool and researchers gain access to an unprecedented source of truth.

Rebuilding the System Around the Patient

Novellia's model represents a fundamental shift in data ownership and agency. Instead of patients being the passive subjects of data collection, they become active, empowered participants. The platform allows an individual to connect to a vast network of over 50,000 healthcare systems and, within seconds, unify up to two decades of their medical records into a single, secure, and user-friendly interface. This service is free for the patient. The business model activates only when a patient explicitly consents to share their anonymized, de-identified data with researchers.

This consent-driven framework is critical. It taps into a well-documented desire among patients to contribute to medical progress, a willingness often stymied by a lack of trustworthy infrastructure. As Emma Silverman, Partner at investor TMV, noted, "Nearly 70% of patients are open to contributing data for medical breakthroughs, but they expect control, transparency, and privacy safeguards." Novellia is building the bridge across that gap. By providing clear terms and robust privacy protections, the company is creating a new category of patient-consented data that is not only more ethically sourced but also more scientifically valuable.

This approach has already gained significant traction. Novellia has secured multi-year, seven-figure contracts with several of the world's top 10 pharmaceutical companies, validating the market's hunger for a better solution. For these clients, the platform offers a way to de-risk drug development, accelerate research timelines, and gain insights that were previously impossible to obtain.

The Ripple Effect in the Lab

The strategic implications for pharmaceutical R&D are profound. Access to complete, longitudinal data directly from the source allows researchers to answer questions with far greater confidence. For instance, Novellia helped one client analyze safety signals for a breast cancer drug, discovering that the incidence of a suspected adverse event was lower in the real world than feared. In another project, its data revealed significant variations in biomarker testing patterns between academic centers and community clinics, highlighting care gaps that impact patient outcomes.

This is the kind of granular insight that investors are betting on. "I've known major pharma companies had data that was too old, too slow, and too disconnected from patients," said Alex Finkelstein, General Partner at Spark Capital, who led the Series A round. "For a long time, I looked for a company like Novellia. Shashi understood the problem firsthand and built the solution that benefits patients and research." Finkelstein's conviction underscores a broader market realization: the old way of doing things is no longer tenable. The competitive advantage will go to companies that can access the highest-quality data fastest, and Novellia is positioning itself as the premier conduit for that data.

The AI Engine Turning Text into Insight

Simply aggregating records, however, is only half the battle. The true magic—and a core component of Novellia's intellectual property—lies in its ability to interpret the data. A significant portion of a patient's story is locked away in unstructured text: the detailed notes a physician types during a visit, the narrative summary on a pathology report, or the reasoning behind a radiologist's findings. This is often the richest layer of the medical record, containing the clinical nuance and context that structured data fields miss.

Novellia employs proprietary AI and Natural Language Processing (NLP) models to mine this unstructured text. These algorithms are trained to understand clinical language, extracting key signals, timelines, and decision-making rationale. This process transforms a chaotic collection of documents into a harmonized, research-grade dataset where the 'why' behind a diagnosis or treatment decision becomes visible. The new funding will be used to further scale this sophisticated AI infrastructure, expanding its ability to turn raw patient data into actionable scientific intelligence.

By building its platform at the intersection of patient empowerment and advanced AI, Novellia is doing more than just disrupting the RWD market. It is creating a new framework for medical discovery, one where progress is accelerated not by scraping data from the sidelines, but by inviting patients to the very center of the research process.